United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M

UNITED THERAPEUTICS Corp

2023-Q3 EPS reported $15.48 revenue$1,712,800,000

Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.
Tyvaso DPI sales $205.1M (+225%) drove total Tyvaso $325.8M (+26%); nebulized Tyvaso declined 38% to $120.7M.
Remodulin $131.1M (+15%), Orenitram $92.0M (+5%), Unituxin $51.3M (+11%).
R&D expense $84.7M (+28%) from TETON fibrosis studies and organ manufacturing; SG&A $127.6M (+30%).
CEO cites record quarterly revenue; pipeline data expected in 2025; management reaffirms ~$4B annual run rate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2023 results: revenue $609.4 million, net income $267.6 million, EPS $5.38 per diluted share.

Period: the quarter ended September 30, 2023
Revenue: $609.4 million
Net income: $267.6 million
EPS: $5.38 per diluted share
Result: reported results

Exact text from the filing

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001082554-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.